• <code id="6nud9"></code>
  • <th id="6nud9"></th>
      <code id="6nud9"></code>

        Cell Proliferation Industry~Research Base (Shenzhen)
        Position: Home  /  News  /  Company News
        Cell Proliferation Industry~Research Base (Shenzhen)
        Cell Proliferation Industry~Research Base (Shenzhen)


        Dr. Yanmei Wang, Secretary General of Shenzhen Life Science and Biotechnology Association, announcing the start of the forum

        “Focus on early cancer screening, promote human health.” On November 24, the opening for the "2019 Shenzhen (International) Early Screening and Prevention and Control Innovation Forum for Cancer" co-sponsored by China Health Promotion Foundation, Beijing Medical Awards Foundation and Shenzhen Life Science and Biotechnology Association, was officially held.  During this event, hundreds of leaders and experts from the medical fields from both domestic and abroad carried out a vibrant discussion on the innovation and development opportunities of early cancer screening technology, and jointly witnessed the unveiling of the “Shenzhen Cell Proliferation Research Base”. This marks a defining stage in the industry for the early screening of cancer using cell proliferation detection technology!

        Mr. Shuzhong Bai addressing the forum

        According to the "Healthy China 2030 Action Plan", it proposes "to actively prevent cancer, promote early screening, early diagnosis, early treatment, and reduce cancer morbidity and mortality." Dr. Yanmei Wang, Secretary-General of Shenzhen Life Science and Biotechnology Association and host of the forum, said that due to Shenzhen’s “dual-zone drive” strategy, it should rely on its own advantages to pioneer the field of early screening of cancer. Furthermore, it should be willing to take risks innovating new  benchmarks of the industry. In his speech at the conference, Shuzhong Bai, Lifetime Honorary Director of China Health Promotion Foundation, fully affirmed Shenzhen's positive experience and achievements in the application of cell proliferation detection technology in the field of early screening of cancer. He believes that the innovation and application of appropriate technology as well as the framework of healthy prevention and treatment of cancer should be promoted, and of great significance for the implementation of the National Cancer Control Action Plan.

        Professor Wanqing Chen giving a speech

        Prof. Sven Skog’s Speech

        Professor Wanqing Chen, director of the Office of Early Diagnosis and Early Treatment of the National Cancer Center, introduced China’s current cancer epidemic status screening strategies at the forum. Professor Sven Skog, Honorary Director of Shenzhen Sino-Swed Tongkang Institute of Precision Medicine, introduced the basic principles and application technologies of the cell proliferation detection biomarker TK1. Likewise, Professor Weiqing Wu of Shenzhen People's Hospital focused on sharing the applications and related research trends of cell proliferation markers in daily physical examination. Dean Xizhuo Sun of Shenzhen Luohu Hospital Group made raised an interesting topic on how the community health consortium platform can support the early screening of cancer.

        Post-speech open discussion

        In addition, Jingbo Li, Geng Tian, Shubin Wang, Yan Wang, and other experts in cancer clinical and health management from all over the country also started a thrilling dialogue on the application of cell proliferation detection technology in early screening of cancer.

        Cell proliferation detection technology is based on the accurate detection of thymidine kinase 1 (TK1), an internationally recognized cell proliferation marker. By quantitatively determining the rate and status of cell proliferation, it is possible to determine the risk and development of cancer early in the precancerous lesion stage where the tumor has not yet formed Process, so as to advance the early screening of cancer, so that early warning and intervention can be made to reduce the incidence of cancer. The Swedish Karolinska Institute is a global leader in the research of this detection technology, and Shenzhen Sino-Swed Tongkang Precision Medicine Institute is an important carrier for the application and promotion of this technology in China. Over the years, through carrying out application research with more than 110 hospitals across the country, it has published two special books at home and abroad, published 8 SCI papers, and formed a large database of more than 200,000 cases, making Shenzhen the forefront of global cell

        proliferation detection technology!

        Forum guests taking a group photo

        Kevin Zhou, the founder of Shenzhen Sino-Swed Tongkang Precision Medicine Research Institute, introduced that early cancer screening is a systematic project that requires multi-party collaboration from the government, the industry, and the medical research community. Furthermore, reliable technical capabilities are the main appeal of this project. The opening of the “Shenzhen Cell Proliferation Research Base” is not only a demonstration of a decade of development in detection technology, but also marks Shenzhen’s contribution towards the frontier of early cancer screening technology.

        Shenzhen Sino-Swed Tongkang Precision Medicine Research Institute and Le Ting Medical Technology (Shenzhen) Co., Ltd.  contract agreement signing

        Shenzhen Sino-Swed Tongkang Precision Medicine Research Institute and Japan Unified Medical Physician

        Association contract agreement signing

        Witnessed by nearly guests from Japan, Canada, Singapore, Hong Kong, Taiwan, and Mainland China, Shenzhen Sino-Swed Tongkang Precision Medicine Research Institute also partnered with  Le Ting Medical Technology (Shenzhen) Co., Ltd. and Japan Unified Medical Physicians Association, respectively. The partnership agreement on the application and promotion of early cancer screening technology signifies the first collection of landed projects launched by the Shenzhen Cell Proliferation Industry Research Institute.

      1. <code id="6nud9"></code>
      2. <th id="6nud9"></th>
          <code id="6nud9"></code>